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Background
In March 2014, the World Health Organization was notified of an outbreak of Zaire 
ebolavirus in a remote area of Guinea. The outbreak then spread to the capital, 
Conakry, and to neighboring countries and has subsequently become the largest 
epidemic of Ebola virus disease (EVD) to date.
Methods
From March 25 to April 26, 2014, we performed a study of all patients with laboratory-
confirmed EVD in Conakry. Mortality was the primary outcome. Secondary out-
comes included patient characteristics, complications, treatments, and comparisons 
between survivors and nonsurvivors.
Results
Of 80 patients who presented with symptoms, 37 had laboratory-confirmed EVD. 
Among confirmed cases, the median age was 38 years (interquartile range, 28 to 46), 
24 patients (65%) were men, and 14 (38%) were health care workers; among the 
health care workers, nosocomial transmission was implicated in 12 patients (32%). 
Patients with confirmed EVD presented to the hospital a median of 5 days (inter-
quartile range, 3 to 7) after the onset of symptoms, most commonly with fever (in 
84% of the patients; mean temperature, 38.6°C), fatigue (in 65%), diarrhea (in 62%), 
and tachycardia (mean heart rate, >93 beats per minute). Of these patients, 28 (76%) 
were treated with intravenous fluids and 37 (100%) with antibiotics. Sixteen pa-
tients (43%) died, with a median time from symptom onset to death of 8 days (in-
terquartile range, 7 to 11). Patients who were 40 years of age or older, as compared 
with those under the age of 40 years, had a relative risk of death of 3.49 (95% 
confidence interval, 1.42 to 8.59; P = 0.007).
Conclusions
Patients with EVD presented with evidence of dehydration associated with vomiting 
and severe diarrhea. Despite attempts at volume repletion, antimicrobial therapy, and 
limited laboratory services, the rate of death was 43%.
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Ebola virus is one of three members of the Filoviridae family and comprises five distinct species. Infection with Zaire 
ebolavirus (EBOV) has historically resulted in the 
highest case fatality rate — up to 90%.1 Out-
breaks typically originate with introduction of 
the virus into humans from a wild animal reser-
voir, with subsequent human-to-human trans-
mission, often fueled by nosocomial amplifica-
tion in resource-poor settings. Aside from a single 
infection with Tai Forest ebolavirus, West Africa has 
never had an outbreak of Ebola virus disease 
(EVD).2,3
The Republic of Guinea, on the west coast of 
Africa, has a population of approximately 11 mil-
lion persons, a life expectancy at birth of 58 years, 
and an annual gross national income of 970 inter-
national dollars, with an expenditure on health 
care of 67 international dollars per capita per 
year.4 Conakry, the capital and largest city, with 
an approximate population of 2 million persons, 
is served by a number of large hospitals, including 
Donka Hospital (the major public and university-
affiliated medical center), Ignace Deen Hospital, 
and the Hôpital de l’Amitié Sino-Guinéenne, in 
addition to a number of privately funded health 
clinics.
On March 21, 2014, the World Health Orga-
nization (WHO) was formally notified of a rap-
idly evolving outbreak of EVD centered in the 
prefecture of Guéckédou, in the forested region 
of southeastern Guinea, with potential spread 
to border areas in Liberia and Sierra Leone.5 
Infected travelers from Guéckédou subsequent-
ly initiated chains of transmission of EVD in 
Conakry, more than 600 km away, marking the 
world’s largest urban EVD outbreak and herald-
ing the largest ever EVD epidemic, involving 
Guinea, Sierra Leone, Liberia, Nigeria, Senegal, 
and Mali.6 A concurrent but epidemiologically 
unrelated outbreak has also been recognized in 
the Democratic Republic of Congo.6
The care of patients with EVD in Conakry 
initially occurred at two sites: the Hôpital de 
l’Amitié Sino-Guinéenne, which mainly focused 
on a large nosocomial outbreak affecting health 
care workers, and a stand-alone EVD treatment 
unit established on the grounds of Donka Hos-
pital by the Ministry of Health, supported by 
Médecins sans Frontières and the WHO. As of 
October 31, 2014, the Guinea Ministry of Health 
had reported a cumulative total of 1667 clinical 
cases of EVD (with 1018 deaths), including 244 
cases (and 98 deaths) in Conakry; a total of 
13,562 cases (and 4950 deaths) were reported 
throughout West Africa.7 Here we describe de-
mographic and clinical characteristics of the 
patients at presentation, the clinical course of 
EVD, and outcomes of all patients admitted for 
care in Conakry during a 1-month period at the 
onset of the outbreak.
Me thods
Study Design
We conducted a retrospective, observational 
study of all patients with suspected or confirmed 
EVD who were admitted for care in Conakry 
from March 25 to April 26, 2014 (Fig. S1 in the 
Supplementary Appendix, available with the full 
text of this article at NEJM.org). We used a stan-
dard case definition that was established by the 
WHO and the Guinea Ministry of Health (Table 
S1 in the Supplementary Appendix). Laboratory 
confirmation of EVD was made on the basis of 
results on quantitative reverse-transcriptase–
polymerase-chain-reaction (RT-PCR) assay in a 
laboratory established at Donka Hospital by the 
Institute Pasteur in Dakar, Senegal. Laboratory 
staff members used rapid Taqman RT-PCR assays 
for the detection of EBOV using 5-FAM and 
3-TAMRA tagged probes and a portable Smart-
Cycler TD. EBOV RNA in patient samples was 
measured according to the standard described by 
Weidmann et al.,8 in which the sample is diluted 
to a range of 1 copy to 1 million copies and is 
then tested in quadruplicate to construct a stan-
dard curve for estimating the number of genome 
copies. Follow-up testing for antibodies against 
EBOV by means of enzyme-linked immunosor-
bent assay (ELISA) was performed as needed. Pa-
tients were treated in accordance with protocols 
established for viral hemorrhagic fever by Méde-
cins sans Frontières and WHO urgent interim 
guidance for case management, endorsed by the 
Ministry of Health.9,10
Data Collection
Data-collection forms encompassed epidemio-
logic and demographic data, exposure history, 
occupation and recent travel, symptoms, onset 
date, vital signs at admission, and medical his-
tory. Also recorded were daily symptoms, vital 
signs, complications, treatments, laboratory test 
results when available, and outcomes. The clini-
cal care team collected data from patients who 
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were admitted to EVD treatment units. Admis-
sion data were reviewed daily by clinicians. Ap-
proval and a waiver from the need to provide 
written informed consent were obtained from 
the ethics review committees for the Guinean 
government and the WHO.
Statistical Analysis
We used Student’s t-test, Fisher’s exact test, or 
the Wilcoxon rank-sum test, as appropriate, to 
determine the association between mortality and 
the clinically informed variables of age, sex, oc-
cupation, the presence of gastrointestinal hem-
orrhage, the number of days between symptom 
onset and presentation, and viral load at presen-
tation. We used Kaplan–Meier methods and log-
rank tests to determine survival curves for vari-
ous groups of patients, using the interval from 
the onset of symptoms to death for those who 
died within 28 days, with data censored at 28 
days for survivors. We explored associations be-
tween the above-mentioned variables and death 
in univariate analyses.
We used a multivariate Poisson regression 
analysis with robust standard errors to investi-
gate our three primary clinically informed hy-
potheses: that mortality was associated with 
older age, an increased interval from symptom 
onset until presentation to a treatment facility, 
and an increased viral load.11,12 We examined 
survival according to age using a scatter plot and 
5-year age bins to determine the most appropri-
ate dichotomous age comparisons. We log-
transformed viral loads for primary compari-
sons among survivors and nonsurvivors and 
performed sensitivity analyses dichotomizing 
viral loads using two sets of values (less than the 
sample median vs. greater than or equal to the 
sample median and <100,000 copies per millili-
ter vs. ≥100,000 copies per milliliter). All statis-
tical tests were two-tailed, with a P value of less 
than 0.05 considered to indicate statistical sig-
nificance. All analyses were performed with the 
use of SAS software, version 9.3 (SAS Institute), 
and R software, version 2.15.1.
R esult s
Study Patients
Eighty patients who had symptoms meeting the 
definition of suspected EVD were admitted to the 
two treatment facilities in Conakry. Among these 
patients, 37 (46%) were confirmed to have EVD, 
36 (97%) by means of RT-PCR and 1 who had 
negative results on RT-PCR assay but had positive 
results for IgG antibodies on ELISA (Table 1). 
The latter patient had a clinical syndrome com-
patible with EVD and was a close contact of an-
other patient with confirmed disease.
The median age of the confirmed cases was 
38 years (range, 19 to 61), and 24 (65%) were 
men. The most common mechanism of contact 
was through household clusters, which account-
ed for 23 cases (62%). Fourteen patients (38%) 
Table 1. Characteristics, Symptoms, Vital Signs, and Time Course of Clinical 
Progression of 37 Patients with Confirmed Ebola Virus Disease (EVD).*
Variable Value
Median age (IQR) — yr 38 (28–46)
Male sex — no. (%) 24 (65)
Health care worker — no. (%)
Yes 14 (38)
No 23 (62)
Known mechanism of contact — no./total no. (%)†
Health care 12/34 (35)
Household 23/37 (62)
Funeral 6/37 (16)
Known coexisting medical condition — no. (%)
Hypertension 2 (5)
Human immunodeficiency virus 2 (5)
Diabetes 1 (3)
Renal insufficiency 1 (3)
Tuberculosis 1 (3)
Malaria at presentation — no. (%) 4 (11)
Symptoms — no./total no. (%)
Fever 31/37 (84)
Fatigue 24/37 (65)
Diarrhea 23/37 (62)
Headache 12/21 (57)
Vomiting 21/37 (57)
Anorexia 16/37 (43)
Vital signs at admission
Temperature — °C 38.6±1
Heart rate — beats/min 93±14
Systolic blood pressure — mm Hg 125±25
Median interval from onset of symptoms (IQR) — days
To hospital admission 5 (3–7)
To death 8 (7–11)
* Plus–minus values are means ±SD. IQR denotes interquartile range.
† Some patients had more than one exposure.
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were health care workers, in whom nosocomial 
transmission was implicated in 12 of 34 patients 
(35%). Participation in funeral ceremonies of 
confirmed cases was an additional risk factor 
for 6 of these patients (16%).
Clinical features at presentation were nonspe-
cific and included fever in 31 patients (84%; 
mean temperature, 38.6°C), fatigue in 24 patients 
(65%), gastrointestinal symptoms (in 23 patients 
with diarrhea [62%] and 21 with vomiting 
[57%]), headache in 12 of 21 patients who were 
evaluated (57%), and anorexia in 16 patients 
(43%) (Table 1). At admission, patients had mild 
tachycardia (mean [±SD], 93±14 beats per min-
ute) with a mean systolic blood pressure of 
125±25 mm Hg. Hiccups occurred in 28% of 
patients during the period of hospitalization. 
The median time from symptom onset to pre-
sentation was 5 days (interquartile range, 3 to 7), 
and the median time from symptom onset to 
death was 8 days (interquartile range, 7 to 11).
Oral rehydration solution was given to 36 pa-
tients (97%), and 28 patients (76%) received ad-
ditional intravenous fluid resuscitation (Table 2). 
A median of 1 liter of intravenous crystalloids 
was administered during the first 24 hours after 
admission. Antibiotics were administered empiri-
cally in 37 patients (100%) with gastrointestinal 
symptoms, and artemisinin-based combination 
therapy was administered in 7 patients (19%), of 
whom 4 had confirmed Plasmodium falciparum 
infection on rapid diagnostic testing. One pa-
tient (3%) received supplemental oxygen therapy 
for hypoxemia.
For the first 3 weeks of the outbreak, no rou-
tine clinical laboratory testing was available. For 
approximately 1 week, we used an i-STAT System 
point-of-care device with CHEM8+ and CG4+ 
cartridges (Abbott Point of Care) to perform lim-
ited diagnostic testing in 3 patients with clinical 
symptoms in the treatment center. In 1 patient, 
we found severe prerenal kidney dysfunction 
(creatinine, 13.9 mg per deciliter [1229 μmol per 
liter]; and blood urea nitrogen, >140 mg per deci-
liter [>50.0 mmol per liter]) and accompanying 
metabolic acidosis (pH, 7.21; and lactate, 7.4 mmol 
per liter), results that improved after the admin-
istration of approximately 5 liters of intravenous 
crystalloid fluids per day for 3 days (creatinine, 
2.4 mg per deciliter [212 μmol per liter]; blood 
urea nitrogen, 40 mg per deciliter [14.3 mmol 
per liter]; pH, 7.46; and lactate, 1.1 mmol per 
liter). Similar findings were noted in a second 
patient (creatinine, 4.9 mg per deciliter [433 μmol 
per liter]; and blood urea nitrogen, 73 mg per 
deciliter [26.1 mmol per liter]), findings that 
were probably caused by profound diarrhea 
(potassium, 2.4 mmol per liter; and bicarbonate, 
15 mmol per liter), which also resolved after the 
administration of approximately 4 liters of intra-
venous crystalloid f luids per day for 3 days 
along with potassium. Among 3 patients in whom 
anemia was suspected, including 1 patient with 
clinical evidence of lower gastrointestinal bleed-
ing, hematocrit levels were not profoundly low 
(mean, 31.2±3.4).
Among the 16 patients (43%) who died, the 
median duration of hospital stay was 5 days, as 
compared with 9 days (interquartile range, 6 to 
11) among survivors. The most common clinical 
complication was hemorrhage, which was report-
ed in 19 patients (51%), most frequently gastro-
intestinal bleeding (in 9 patients), of whom 8 pa-
tients had melena and 1 patient each had 
hematemesis and hematochezia (Table 3).
In univariate analyses, the viral load appeared 
to be higher among patients who died than in 
survivors (Table 4), but this finding was influ-
enced by the deaths of all 4 patients who had a 
viral load of more than 100,000 copies per mil-
liliter on admission, and viral load was not signifi-
cantly associated with death on nonparametric 
testing. Mortality was not significantly higher 
among the few patients who had coexisting con-
ditions than in those without such conditions 
(57.1% vs. 40.0%, P = 0.44). However, an older 
Table 2. Therapies Received by 37 Patients Hospitalized for EVD.
Therapy Value
Oral rehydration solution — no. (%) 36 (97)
Intravenous fluids — no. (%) 28 (76)
Median volume of crystalloid solution administered in first  
24 hr (IQR) — liters
  1 (1–1)
Antibiotic treatment — no. (%)
Any  37 (100)
Ciprofloxacin 20 (54)
Ceftriaxone 13 (35)
Cefixime  5 (14)
Amoxicillin–clavulanic acid 1 (3)
Antimalarial treatment — no. (%)  7 (19)
Supplemental oxygen therapy — no. (%) 1 (3)
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age was associated with an increased risk of 
death, with a median age of 29 years in survivors 
as compared with 45 years in those who died 
(P = 0.005) (Fig. 1). In a multivariable Poisson 
regression analysis that was adjusted for age, 
viral load, and time from symptom onset to 
presentation, patients who were 40 years of age 
or older had a relative risk of death of 3.49 (95% 
confidence interval [CI], 1.42 to 8.59), as com-
pared with those under the age of 40 years 
(P = 0.007). There were no significant differences 
between survivors and nonsurvivors in the num-
ber of days between symptom onset and admis-
sion (relative risk in survivors, 0.94; 95% CI, 0.86 
to 1.04; P = 0.22) and viral load on admission 
(relative risk, 0.98; 95% CI, 0.91 to 1.07; P = 0.72).
Discussion
Patients, on average, presented 5 days after 
symptom onset, and the most common manifes-
tations of EVD during hospitalization were fever, 
vomiting, diarrhea, and related volume depletion 
requiring the administration of intravenous flu-
ids and electrolyte therapy. Overall mortality 
among patients presenting for treatment was 
43%, and only the age of the patient was a sig-
nificant predictor of outcome. In contrast to pre-
vious Ebola virus outbreaks in which an older age 
was also associated with a worse outcome, the 
mean age of nonsurvivors in our study was 
low.13,14 The association between an older age 
and a worse outcome among patients with viral 
infections is often attributed to an increased 
number of coexisting conditions. However, in 
our study, the relative absence of known coexist-
ing conditions suggests that an older age may 
have an independent association with mortality. 
We also found that patients who presented for 
care with the highest viral loads were the least 
likely to survive, as has been shown for other 
strains of Ebola virus.15 After adjustment for dif-
Table 3. Clinical Complications and Outcomes for 37 Patients with EVD.
Variable Value
Hospital mortality — no. (%) 16 (43)
Median length of stay in hospital (IQR) — days 8 (6–11)
Known complications in hospital — no. (%)
Hemorrhage
Any 19 (51)
Gastrointestinal 9 (24)
Subconjunctival 4 (11)
Intravenous catheter site 4 (11)
Nasorespiratory tract 2 (5)
Renal failure* 2 (5)
Seizure 2 (5)
Oral candidiasis 1 (3)
Hypoxemia 1 (3)
* Renal failure was defined as a serum creatinine level of more than 4 mg per 
deciliter (350 μmol per liter).
Table 4. Characteristics of Survivors and Nonsurvivors.
Characteristic
Survivors  
(N = 21)
Nonsurvivors
(N = 16) P Value
Median age (IQR) — yr 29 (26–37) 45 (40–47) 0.005
Male:female ratio 14:7 10:6 1.00
Viral load at admission
Mean ±SD — copies/ml 8207±17,189 68,361±111,340 0.02
Median (IQR) — copies/ml 1079 (148–5059) 1915 (141–12,998) 0.47
>100,000 copies/ml — no. (%) 0  4 (25) 0.02
Health care worker — no. (%) 6 (29)  8 (50) 0.31
Clinical features
Hemorrhage — no. (%)
Any visible 8 (38) 11 (69) 0.1
Gastrointestinal 4 (19)  6 (38) 1.0
Interval from symptom onset to presentation (IQR) — 
days
5 (4–8)  5 (2–7) 0.49
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ferences in age and time to presentation, this 
relationship was not significant. However, our 
study had limited power to detect all predictors 
of outcome because of the small number of pa-
tients.
The case fatality rate that we observed in this 
cohort in the capital city of Conakry was lower 
than the rate reported in most studies of previ-
ous EVD outbreaks1 (although not in all stud-
ies7) and was lower than the rate in most other 
regions in Guinea at that point in the epidem-
ic.7,13 Clinical care at the main isolation facility 
near Donka Hospital was jointly provided by the 
Ministry of Heath, Médecins sans Frontières, 
and the WHO during the study period. Adher-
ence to new guidelines promoting increased 
medical interventions, particularly related to the 
use of oral and intravenous fluids and electrolyte 
replacement, appropriate antibiotics, and targeted 
clinical laboratory testing,9 may have contribut-
ed to the reduced case fatality rate, as compared 
with past outbreaks. However, assessing associa-
tions between treatments and outcomes in small 
observational studies is challenging. In our 
study, there were approximately three clinical 
rounds per day, with two or three doctors and 
two or three nurses for each round, and depend-
ing on the type of personal protective equipment 
that was used, rounds were limited to either 1 hour 
or 3 hours because of the intense heat and hu-
midity inside some types of personal protective 
equipment. Although we attempted to deliver 
oral and intravenous fluids to correct dehydra-
tion and metabolic abnormalities, care was still 
suboptimal. With more clinical personnel in each 
treatment center, better supportive care could be 
delivered more consistently, and we think that 
mortality could be driven lower.
The predominant clinical syndrome of EVD 
involves substantial volume loss due to vomiting 
and diarrhea. This requires aggressive oral and 
intravenous volume repletion and close follow-
up to avoid further complications and hypoper-
fusion-associated organ dysfunction. Point-of-care 
diagnostic testing provided additional insights 
in a small number of patients, suggesting inad-
equate tissue perfusion — lactic acidosis, base 
deficits, prerenal kidney dysfunction, and low 
venous oxygen saturations. However, we could 
not perform such testing early or frequently 
enough to properly define the patterns. The sub-
stantial volume loss and profound electrolyte 
derangement from copious diarrhea represent 
opportunities to intervene clinically to improve 
outcomes. Notably, hypoxemia was rarely seen 
in these patients, despite attempts at aggressive 
volume repletion. However, this finding may still 
represent inadequate volume administration, and 
hypoxemia caused by pulmonary vascular leak 
may be more common in other care settings. 
Consideration may also be given to the empirical 
use of antimalarial therapy, especially if rapid 
diagnostic testing is not immediately available. 
Patients with severe gastrointestinal symptoms 
were also routinely treated with a finite empiri-
cal course of antibiotics with activity against 
gram-negative, gram-positive, and anaerobic or-
ganisms. However, the effect of this intervention 
remains unknown.
As has been seen in other disease outbreaks, 
but never before with EVD, large urban settings 
present special challenges to emergency health 
care facilities, and nosocomial transmission 
among health care staff members and patients 
represents an important potential outbreak am-
plification and new lines of transmission.16,17 
This finding highlights the importance of rapid 
support for infection control, not only in dedi-
cated isolation facilities but also within existing 
treatment centers that will typically receive un-
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Figure 1. Kaplan–Meier Estimate of the Probability of Survival among Patients 
with Ebola Virus Disease, According to Age.
The New England Journal of Medicine 
Downloaded from nejm.org at LONDON SCH HYGIENE & TROPICAL MED on April 12, 2019. For personal use only. No other uses without permission. 
 Copyright © 2015 Massachusetts Medical Society. All rights reserved. 
T h e  n e w  e ngl a nd  j o u r na l  o f  m e dic i n e
n engl j med 372;1 nejm.org january 1, 201546
differentiated patients with fever and nonspe-
cific symptoms. Infection-control practices to 
protect patients and health care workers can 
have unanticipated negative consequences, in-
cluding fewer clinical assessments, which may 
be compounded by limited clinician time at the 
bedside because of heat exposure in personal 
protective equipment.18,19
Limitations of our study include reliance on 
estimates from a discrete but relatively small 
cohort of patients. However, the observed mor-
tality in Conakry (43%) has remained relatively 
stable (40%) between April and October 2014.20 
Despite an active public health system for trac-
ing contacts, case finding, and referral to an 
acute care facility, we inevitably are unable to 
identify all patients with suspected and con-
firmed EVD, since some will choose not to pre-
sent to health care facilities and some will die 
before seeking medical attention. This potential 
selection bias will underestimate the number of 
cases and have uncertain effects on the case fa-
tality rate for this epidemic. The inclusion of 
only patients who could be transported to our 
health care facilities may lead to a survivorship 
and immortal time bias, since patients with EVD 
needed to have survived long enough to get to a 
facility in order to be described and to receive 
certain treatments. Furthermore, selection of 
patients for certain treatments is subject to bias 
according to indication, which can lead to an 
overestimation of harm for certain therapies.21 
Therefore, in this observational study, we are 
unable to validly explore relationships between 
treatments received and clinical outcomes, 
which underscores the importance of enhanced 
strategies for supportive care and specific thera-
pies in future clinical trials.
Our recording of simple clinical data was also 
limited by an inability to take any material, in-
cluding paper, outside the treatment center, by 
limited electricity to power onsite electronic data 
capture, and by unreliable Internet access. Inside 
the treatment facility, with too few clinical staff 
members, there is often a trade-off between de-
livering and recording care. A further limitation 
is the paucity of basic data regarding blood chem-
istry and hematology that would better charac-
terize metabolic abnormalities and help to direct 
care for future patients. Point-of-care testing 
inside treatment centers is challenging because 
of a lack of time to perform testing due to high 
temperatures and dehydration of health care 
providers. Routine deployment of basic chemis-
try and hematology analyzers in addition to RT-
PCR assays for EBOV in international mobile 
laboratories would alleviate this limitation and 
may guide further improvements in patient care.
In conclusion, we found that among patients 
admitted to the hospital with confirmed EVD in 
Conakry, Guinea, the most common clinical 
syndrome was one of gastrointestinal illness, 
intravascular volume depletion, and related com-
plications, which highlight the importance of 
enhanced levels of clinical assessment and diag-
nostic testing, along with fluid management.
Disclosure forms provided by the authors are available with 
the full text of this article at NEJM.org.
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